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Abstract
Objective To compare the survival and risk of serious adverse events
in older patients with stages II-IIIA non-small cell lung cancer treated
with or without postoperative platinum based chemotherapy.
Design Observational cohort study.
Setting Cases of lung cancer in Surveillance Epidemiology and End
Results registry linked to Medicare files, 1992-2005, and follow-up data
to December 2007.
Participants 3324 patients aged more than 65 years with resected
stages II-IIIA lung cancer.
Main outcome measures Primary outcome was overall survival and
secondary outcome was the rate of serious adverse events among older
patients treated with or without adjuvant chemotherapy.
Results Overall, 21% (n=684) of patients received platinum based
chemotherapy. Analyses adjusted, stratified, or matched by propensity
scores showed that chemotherapy was associated with improved survival
(hazard ratio range 0.78-0.81). The beneficial effect of chemotherapy
was also observed among patients treated with radiation therapy
(0.75-0.77) or without radiation therapy (0.74-0.77); however,
chemotherapy was not beneficial for patients aged 80 or more
(1.32-1.46). Adjuvant chemotherapy was associated with an increased
odds of serious adverse events (odds ratio 2.0, 95% confidence interval
1.5 to 2.6).
Conclusions Platinum based adjuvant chemotherapy is associated with
reduced mortality and increased risk of serious adverse events in older
patients with stages II-IIIA lung cancer. The magnitude of the benefit is
similar to that observed in randomised controlled trials carried out among
selected patients.
Introduction
Lung cancer is predominately a disease of older people, with
themedianageatdiagnosisintheUnitedStatesbeing69years.
1
By 2030 an estimated 20% of the US population will be older
than 65.
2 Given the increasing life expectancy and the higher
incidence of lung cancer in older people, the management of
such patients with resectable non-small cell lung cancer should
become increasingly common in clinical practice.
About 40% of patients with non-small cell lung cancer present
with stages I to IIIA disease, which may be amenable to
resection and is potentially curable.
3 4 Patients with stage I
non-small cell lung cancer have five year survival rates of
around 70% and are usually observed after surgical resection.
5
Conversely, 40-65% of patients with stage II or IIIA disease
who have undergone resection experience recurrence and may
ultimately die from disease progression.
6 Several phase III
randomisedcontrolledtrialshaveshownthebenefitofadjuvant
platinum based chemotherapy in patients with stages II-IIIA
non-small cell lung cancer.
7-9 10 Recent meta-analyses of these
trials also showed a survival advantage of adjuvant platinum
based chemotherapy.
11-15 As a result, current guidelines
recommend the use of adjuvant chemotherapy as the standard
ofcareforpatientswithstagesII-IIIAnon-smallcelllungcancer
who have undergone resection.
16
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Research
RESEARCHRandomised controlled trials of cancer are carried out under
highly standardised protocols. Although the internal validity of
these trials is strong, the generalisability of the results to older
patients with lung cancer is unclear. Most of the studies
evaluating the efficacy of adjuvant chemotherapy in non-small
cell lung cancer enrolled highly selected participants with good
functional status and a low number of comorbidities; thus
including a limited number of older participants.
7 9 10 17 18
Consequently, the observed benefit and adverse effects of
adjuvant chemotherapy in these randomised controlled trials
may not reflect those expected for older patients treated in
routine clinical practice. This lack of evidence on the
effectiveness of adjuvant chemotherapy in older patients and
concerns about greater risks of adverse events might lead to
under-treatment and increased lung cancer mortality among
such patients with non-small cell lung cancer.
We used data from the Surveillance Epidemiology and End
Results(SEER)registry,anationallyrepresentative,population
baseddatasourceoncancer,linkedtoMedicarefilestocompare
survival outcomes and rates of serious adverse events among
older patients with stages II-IIIA non-small cell lung cancer
treated with or without platinum based adjuvant chemotherapy
in routine clinical practice.
Methods
The study was carried out with the 2009 release of the
SEER-Medicare linked database, which includes cases of lung
cancer diagnosed up to 2005 and follow-up data to December
2007.TheSEERregistrykeepsanationaldatabasethatcollects
information on all incident cases of cancer in selected areas of
the United States, covering nearly 26% of the US population.
19
From the SEER-Medicare database we selected patients aged
more than 65 years with a diagnosis of stages II-IIIA non-small
cell lung cancer between 1992 and 2005 and who underwent
surgical resection (lobectomy or pneumonectomy). Among
these cases we excluded patients in healthcare maintenance
organisations or those without part B Medicare insurance
(coverage for outpatient care) for whom we were not able to
ascertain comorbidities and use of chemotherapy.
20 We also
excluded patients who died during the perioperative period
(within30daysofsurgery)orwhoweredischargedtoanursing
home after surgery, as they would have not been candidates for
adjuvant chemotherapy. The final cohort consisted of 3324
patients with stages II-IIIA non-small cell lung cancer.
From the SEER-Medicare database we obtained
sociodemographic information on characteristics such as age,
sex, race or ethnicity, marital status, and estimated income. To
evaluate the burden of comorbidities, we used the Deyo
adaptation of the Charlson comorbidity index, applying lung
cancer specific condition weights as described in the
literature.
21-23 From the SEER database we obtained data on
tumour location, size, extension, involvement of lymph nodes,
andhistology.Weclassifiedhistologicalsubtypesintocategories
ofadenocarcinoma,bronchioalveolarcarcinoma,squamouscell
carcinoma, large cell carcinoma, and other histological type.
We examined surgical treatment using information from the
SEER-Medicare database.
24 Using these data, we classified
patients as having either a lobectomy or a pneumonectomy
(SEER site specific surgical codes 30 to 70). From Medicare
inpatient, outpatient, and physician files we identified those
patients who experienced postoperative complications
(extrapulmonary infections, cardiovascular complications,
thromboembolicevents,respiratorycomplications,reoperations,
and transfusions) within 30 days of surgery.
25-27
Use of radiation therapy was ascertained from the SEER
databaseandMedicareclaims.Weclassifiedpatientsashaving
received radiotherapy if they were coded in the SEER database
ashavingreceivedexternalbeamradiationorifMedicareclaims
contained any code indicating use of radiation therapy within
six months of cancer diagnosis. From Medicare files we
identified patients treated with adjuvant chemotherapy. Using
validatedalgorithms,weclassifiedpatientsasbeingtreatedwith
chemotherapy if Medicare inpatient, outpatient, or physician
claims contained any code indicating that the patient received
platinumbasedchemotherapywithinthreemonthsofsurgery.
28
Functional status is an important determinant of chemotherapy
use. Although the SEER-Medicare database does not include
information on patients’ functional status, all the study
participants were eligible for surgery, which should have
effectively excluded patients with poor functional status. To
indirectly assess patients’ postoperative functional status, we
used data from the Home Health Agency file to ascertain use
ofhomehealthservicessuchashomehealthaide,physiotherapy,
speech therapy, occupational therapy, and medical social
services.Asbeneficiariesmustbehomeboundtobeeligiblefor
Medicare home services, we used this information as a proxy
for poor functional status.
The primary study outcome, determined from Medicare data,
wasoverallsurvival.UsinginformationintheMedicarefilewe
calculated survival times as the period from surgery to the date
of death. We classified those surviving past 31 December 2007
(alive at the end of follow-up) as censored observations. The
secondarystudyoutcomewastherateofseriousadverseevents
among older patients who did or did not receive adjuvant
chemotherapy.Usingapublishedalgorithm,wedefinedserious
adverse events as those requiring admission to hospital within
2-6 months of surgery (the usual period for occurrence of
chemotherapy related adverse events). Serious adverse events
wereinfection,fever,neutropenia,anaemia,thrombocytopenia,
dehydration, nausea or emesis, acute renal dysfunction, and
unspecified adverse events of systemic therapy.
29 Additionally,
we evaluated the number of patients who died within 12 weeks
of initiation of chemotherapy (the typical duration of platinum
based regimens) and number of patients with a diagnosis of
neuropathy, a potential long term adverse event from
chemotherapy, within two years of resection.
Statistical analysis
The χ
2 test was used to evaluate differences in the distribution
of baseline characteristics between patients who did or did not
receive postoperative platinum based chemotherapy. We used
propensityscoremethodstocontrolforpotentialselectionbias.
The propensity score is a measure of the probability that a
patient will receive adjuvant chemotherapy after resection on
the basis of their baseline characteristics. We calculated
propensity scores using a logistic model that included the
patients’ sociodemographic characteristics, comorbidities, and
cancer related factors (tumour location, size, involvement of
lymph nodes, and grade). Additionally, we included dummy
variables in the propensity score model indicating whether the
patients had postoperative complications or received home
services, as these patients were probably less likely to receive
adjuvant chemotherapy. Once the model was fitted, we used
regressionanalysistoevaluatewhetherbaselinecovariateswere
balanced across study groups after adjusting for the estimated
propensity scores.
To compare survival of patients who did or did not receive
adjuvant chemotherapy we used Cox regression analysis
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RESEARCHadjusting for propensity scores in three ways.
30 31 Firstly, we
includedthepropensityscoreasacontinuouscovariateinaCox
model comparing the survival of patients treated with and
without chemotherapy. In a second approach we fitted a
stratified Cox model according to fifths of propensity scores.
Finally, we matched patients based on the propensity scores
and compared the survival of patients treated with and without
adjuvant chemotherapy using a marginal Cox model for
correlated data.
32 Adjuvant chemotherapy may be used in
combination with postoperative radiotherapy. As radiotherapy
is usually given concurrently or after chemotherapy this
covariate was not included in the propensity score model. Thus
we carried out secondary analysis adjusting for and stratifying
the cohort by radiotherapy use to assess the effectiveness of
chemotherapy among patients treated with and without
postoperative radiotherapy. We also did secondary analyses to
assesssurvivalamongpatientstreatedwithandwithoutadjuvant
chemotherapyseparatelyforstageIIandstageIIIAdisease,and
within strata according to the patients’ age at diagnosis (<70,
70-79, and >80 years). Finally, we repeated all the analyses
controlling for year of diagnosis, to adjust for potential time
trends in other aspects of lung cancer care.
The potential association of chemotherapy with increased
survival may be confounded by the patients’ functional status,
an important determinant of treatment. To evaluate this
possibility we carried out a sensitivity analysis to test whether
differencesinfunctionalstatuscouldaccountforthemagnitude
oftheobservedassociationofpostoperativechemotherapywith
survival.
33 In our analysis we used published data on the
prevalence of poor functional status (Eastern Co-operative
Oncology Group functional status >2) among patients with
stagesII-IIIAnon-smallcelllungcancerandtherelativehazard
of death associated with poor functional status, to evaluate the
robustness of our findings across different scenarios.
34 35
We calculated the unadjusted odds for serious adverse events,
with 95% confidence intervals, for patients receiving adjuvant
chemotherapy. To estimate the odds of serious chemotherapy
related adverse events among patients receiving chemotherapy
compared with those not receiving chemotherapy we used
logisticregressionanalysisafteradjustingforpropensityscores.
Allanalyseswere donewithSASsoftware andusingtwotailed
P values.
Results
From SEER-Medicare database 3759 patients aged more than
65 with resected stage IIA, IIB, or IIIA non-small cell lung
cancer were identified. Overall, 435 patients were excluded:
114 had undergone limited resection and 321 were discharged
to a long term care facility; the final cohort consisted of 3324
patients with non-small cell lung cancer. In total, 684 (21%,
95%confidenceinterval19%to22%)patientsreceivedplatinum
basedchemotherapy.Themedianfollow-uptimewas39months.
Table 1 shows the baseline characteristics of these patients.
Those treated with adjuvant chemotherapy were younger
(P=0.02) and more likely to be white (P=0.04) and married
(P=0.001).Thecharacteristicsoftumours(histologyandstage)
alsodifferedsignificantlybetweenpatientstreatedornottreated
with adjuvant chemotherapy (P=0.005 and P<0.001,
respectively). Patients who did not receive adjuvant
chemotherapy had a higher burden of comorbidities (P=0.05)
and were more likely to receive home services (P=0.04). Use
ofpostoperativeradiotherapywasmorecommonamongpatients
receiving adjuvant chemotherapy (P<0.001). Except for
postoperativeuseofradiotherapy,allothercovariateswerewell
balanced among patients treated with and without adjuvant
chemotherapy after adjustment for propensity scores (table 1).
Analyses using a Cox model that included the propensity score
as a covariate showed that adjuvant chemotherapy was
associatedwithsignificantlybetteroverallsurvival(hazardratio
0.80, 95% confidence interval 0.72 to 0.89; table 2). Five year
adjustedsurvivalrateswere35%(95%confidenceinterval32%
to 39%) for patients treated with adjuvant chemotherapy
compared with 27% (25% to 29%) for patients not treated.
Patients who received adjuvant chemotherapy also had
significantly better overall survival in analysis adjusting for
radiotherapy use (hazard ratio 0.77, 95% confidence interval
0.69 to 0.85) or when the analysis was limited to patients who
were treated with radiotherapy (0.77, 0.68 to 0.88) and without
radiotherapy (0.77, 0.64 to 0.91). The results remained
unchanged when the analysis was restricted to patients with
stage II (0.71, 0.60 to 0.83) and stage IIIA disease (0.88, 0.77
to 1.00). Analyses within age strata showed that adjuvant
chemotherapy was associated with improved survival among
patients aged less than 70 years (0.74, 0.62 to 0.88) and 70-79
years(0.82,0.71to0.94);however,thesurvivalbenefitwasnot
observed among patients aged more than 80 years (1.33, 0.86
to 2.06). The survival advantage of patients treated with
chemotherapy persisted when the analyses were repeated using
stratification or matching of study participants by propensity
scores. Secondary analyses also showed that adjuvant
chemotherapy was associated with improved survival after
adjusting for year of diagnosis to control for potential trends in
lung cancer treatment.
Sensitivity analyses showed that potential differences in the
prevalenceofpoorfunctionalstatusamongpatientstreatedwith
and without chemotherapy did not seem to explain the
associationbetweenplatinumbasedchemotherapyandsurvival.
The adjusted association between adjuvant chemotherapy and
improvedsurvivalpersistedevenifuntreatedpatientswerefive
timesmorelikelytohaveapoorfunctionalstatusandthehazard
ratio for poor functional status was 1.5 (adjusted hazard ratio
0.88, 95% confidence interval 0.79 to 0.9; table 3), or poor
functional status was almost three times more common among
untreated patients and the mortality risk for patients with poor
functionalstatuswastwicethatofpatientswithgoodfunctional
status (0.89, 0.80 to 0.99; table 3).
Overall,21patients(3.1%)diedwithin12weeksafterinitiation
ofchemotherapy.Table4showsthepercentageofolderpatients
treated with or without adjuvant chemotherapy who were
admitted to hospital for the diagnoses that might occur as a
serious adverse event. Among patients treated with
chemotherapy, 13.0% were admitted to the hospital for at least
oneofthesediagnosescomparedwith6.9%ofpatientswhodid
not receive chemotherapy (odds ratio 2.0, 95% confidence
interval 1.5 to 2.6). The most common serious adverse events
resulting in admissions to hospital among patients treated with
adjuvantchemotherapywereanaemia(8.6%,n=59),dehydration
(6.7%,n=46),andinfection(5.3%,n=36).Patientswhoreceived
chemotherapyalsohadanincreasedriskofadmissiontohospital
for infection (1.8, 1.2 to 2.7), neutropenia (15.6, 7.1 to 34.1),
dehydration (1.8, 1.3 to 2.7), nausea or emesis (2.9, 1.5 to 5.8),
anaemia (3.1, 2.2 to 4.4), thrombocytopenia (5.1, 1.1 to 23.1),
and unspecified adverse events of systemic therapy (47.1, 6.1
to 363.1). The frequency of admissions to hospital for fever
(1.7, 0.5 to 5.6) and renal dysfunction (0.6, 0.2 to 2.1) did not
differ significantly. The odds for neuropathy within two years
of surgery were also increased among patients treated with
chemotherapy (1.4, 1.2 to 1.7). Similar results were obtained
in analyses adjusting for propensity scores (table 4).
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RESEARCHDiscussion
Several randomised controlled trials have shown the efficacy
ofadjuvantplatinumbasedchemotherapyafterresectionamong
patients with stages II-IIIA non-small cell lung cancer.
9 10 17 18
However, the generalisability of these results to the growing
population of older patients with lung cancer is unclear. Using
population based data, we found that adjuvant platinum based
chemotherapy given to an unselected sample of older patients
with stages II-IIIA non-small cell lung cancer in the non-trial
setting was associated with a similar improvement in survival.
However, patients receiving adjuvant chemotherapy were at
increased risk of serious adverse events requiring admission to
hospital, and the benefit of adjuvant chemotherapy was not
observed among patients aged 80 or more years. Because the
net benefits outweighed potential harms, these data should
encouragedoctorstomorestronglyconsidertheuseofadjuvant
chemotherapy among older patients.
Importance of findings from observational
studies
Randomised controlled trials provide the strongest level of
evidence on the potential efficacy of cancer treatments such as
adjuvant chemotherapy. Patients are randomly allocated to the
study arms protecting against potential imbalances in the
distribution of prognostic factors among study groups.
Consequently, the internal validity of the results of randomised
controlled trials is high. Randomised controlled trials are,
however, usually carried out in highly controlled settings, such
as specialised tertiary care centres, by experienced clinical
teams,followingstandardisedprotocols,withfrequentfollow-up
visits, and are often limited to select younger patients with few
if any major comorbidities. Thus, clinicians may be concerned
aboutextrapolatingresultsfromrandomisedcontrolledtrialsto
older, sicker patients more often encountered in real world
practicesettings.Observationaldatacanbeusefulforassessing
the potential benefit of cancer therapies as used in routine
clinical practice. In this study we validated the results of
randomised controlled trials among a large population based
sample of older patients, suggesting that increased used of
chemotherapy in this population may improve survival
outcomes.
Aswithothersolidtumours,lungcancerprimarilyaffectsolder
people. Despite the high incidence mortality from non-small
celllungcancerinolderpeople,thelikelihoodofreceivingstage
appropriatetreatmentand,inparticular,chemotherapydecreases
withincreasingage.
36 37Datafromchemotherapytrialsdesigned
specifically for older patients with non-small cell lung cancer
are lacking; however, there is limited information from post
hoc analyses of randomised controlled trials about the potential
effectiveness of adjuvant chemotherapy in older people. A
retrospective analysis of the adjuvant vinorelbine and cisplatin
in elderly patients (JBR.10) trial suggested that the benefit of
adjuvant cisplatin based chemotherapy was similar among
patients aged 65 or less compared with those who were older.
38
Similarly, pooled data from randomised controlled trials of
cisplatin based adjuvant chemotherapy also showed similar
improvementsinoverallsurvivalamongpatientsagedlessthan
65, 65-69, and 70 or more.
39 Our results extend these findings
by showing that adjuvant platinum based chemotherapy is
associatedwithimprovedsurvivalinanationallyrepresentative
population of Medicare beneficiaries, which included patients
with multiple comorbidities or suboptimal functional status.
Additionally, our results suggest that adjuvant chemotherapy
is effective when used alone or in combination with radiation
therapy.
Comparativeeffectivenessresearchbasedonobservationaldata
does not provide the same level of evidence about the benefits
ofadjuvantchemotherapyasdoesarandomisedcontrolledtrial.
In observational studies, decisions about use of adjuvant
chemotherapy are influenced by patient preferences, doctors’
judgment, and practice patterns. These factors can generate
systematic differences in the distribution of prognostic factors
among patients treated with and without chemotherapy, which
act as confounders of the effect of treatment. However, in this
studyweusedpropensityscoremethodsandsensitivityanalysis
to control for the potential effect of measured and unmeasured
prognostic factors. Our analyses showed that adjuvant
chemotherapy was associated with a 20% to 25% decreased
hazard of death in older people, a survival advantage similar to
thatreportedinmeta-analysesofrandomisedcontrolledtrials.
14
The results of the sensitivity analyses showed that our results
were robust to a wide range of assumptions about potential
imbalances of the distribution of patients with poor functional
status among the two study groups. Analyses carried out within
age strata suggest that adjuvant chemotherapy is not associated
withimprovedsurvivalinpatientsaged80ormore,thusdoctors
should carefully weigh up the potential benefits and harms of
chemotherapyanddiscussthesewithpatients.Theseresultsare,
however, based on post hoc analyses and the study was not
designed or powered to evaluate the effectiveness of
chemotherapy in the subgroup of patients aged 80 or more.
A common perception among oncologists is that older patients
areatincreasedriskofseriousadverseeventsfromcombination
chemotherapy regimens including platinum based drugs.
40
Moreover, given the limited life expectancy of some older
patients, concerns are that the possible long term survival
benefits of chemotherapy may not offset the potential risk of
treatment related complications. Our study shows that adjuvant
chemotherapy is associated with an increased risk of serious
adverse events requiring admission to hospital. However, the
number of deaths within 12 weeks of starting chemotherapy,
the type of adverse events observed in our cohort, and the rate
of serious adverse event related admissions to hospital were
consistentwiththosereportedinpreviousrandomisedcontrolled
trials among younger patients.
7 9 17 Despite the higher rates of
admissionstohospitalforchemotherapyrelatedseriousadverse
events, there was a net survival benefit for those who received
adjuvant chemotherapy.
Strengths and limitations of the study
Several strengths and limitations of this study should be noted.
Firstly,theSEER-Medicaredatabaseisacomprehensivesource
ofpopulationbasedcancerdata.Levelsofascertainmentwithin
participating areas have been reported to be as high as 98%,
indicating most eligible cases are captured in the registry.
41
Additionally, more than 94% of the patients aged 65 or more
in the SEER registry are included in the SEER-Medicare
database.
42 Thus our results should be highly generalisable to
the older US population as a whole. However, patients aged
less than 65 are not eligible for Medicare (except for those with
disabilityorendstagerenaldisease).Additionally,weexcluded
patientswhowereenrolledinahealthmaintenanceorganisation
or who did not have Medicare part B coverage; thus, we were
not able to assess the effectiveness of chemotherapy among
these groups.
Patients with stage IIIA non-small lung cancer and with
involvement of multiple lymph node stations or bulky
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RESEARCHlymphadenopathy are not generally candidates for primary
resection and are usually treated with combined chemotherapy
and radiotherapy.
43 Unfortunately, the SEER registry does not
include data on the number of lymph nodes stations involved
or the presence of bulky lymph node disease. Although some
of these patients may undergo surgery, resection is generally
carriedoutafterneoadjuvantchemotherapyorradiotherapy.As
we excluded all patients who received neoadjuvant therapy, it
isunlikelythatpatientswithmultipleorbulkylymphadenopathy
wereincludedinthestudycohort.Moreover,thesepatientshave
a worse prognosis and are more likely to receive postoperative
chemotherapy if they undergo resection than patients with less
extensivelymphnodeinvolvement.Thus,theirinclusionwould
bias our results towards the null.
The SEER-Medicare database is one of the largest available
sources of cancer data in the United States. Although the
database contains detailed information on the most important
prognostic factors for lung cancer, it does not include data on
patients’ functional status. All patients in the cohort, based on
theirfunctionalstatus,wereconsideredfitforsurgery.However,
other factors (such as organ dysfunction) may also influence
doctors’ decisions about use of adjuvant chemotherapy in older
patients. We adjusted our analyses for some of these potential
confounders, such as comorbidities and postoperative
complications, and utilised home services use as a proxy for
poorfunctionalstatus.Moreover,sensitivityanalysessuggested
that potential higher rates of poor functional status among
patients who were not treated with adjuvant chemotherapy are
unlikely to explain the observed benefit of chemotherapy.
Aggressive treatment of older patients with lung cancer can
result in serious adverse events; thus, survival benefits may not
be accompanied by improvements in quality of life. These
concerns may be one of the reasons for lower rates of
chemotherapy use among older patients with lung cancer.
Although we could not assess the potential impact of
chemotherapy on quality of life, multiple studies focusing on
older patients and on those with lung cancer or other
malignancies showed that most patients are willing to endure a
relativelypoorqualityoflifeinexchangeforincreasedsurvival
time.
44-46 Additionally, studies show that patients with cancer
are in general willing to accept intensive chemotherapy and
potential adverse effects for a relatively small chance of
benefit.
47-49
Conclusions and clinical implications
Insummary,thesedatasuggestthatolderpatientswithresected
stages II-IIIA non-small cell lung cancer treated with adjuvant
platinum based chemotherapy in routine practice settings have
an improved survival compared with those who do not receive
chemotherapy.Thesurvivaladvantageinthispatientpopulation
is comparable to that observed in younger, highly selected
patients enrolled in previous randomised controlled trials
assessing the efficacy of adjuvant chemotherapy. However,
patients who received chemotherapy in our cohort were at
increased risk of serious adverse events requiring admission to
hospital;afactorthatcannegativelyimpactqualityoflife.Thus
doctors should discuss the potential benefits and disadvantages
of adjuvant chemotherapy with older patients who have lung
cancer before initiating treatment. Given the rapid increase in
the older population with lung cancer, our findings suggest that
more frequent use of adjuvant platinum based chemotherapy in
thispatientpopulationmayimprovepatients’survivaloutcomes.
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RESEARCHTables
Table 1| Baseline characteristics of patients with stages II-IIIA non-small cell lung cancer in Surveillance Epidemiology and End
Results-Medicare database, 1992-2005. Values are numbers (percentages) unless stated otherwise
P value
No adjuvant chemotherapy
(n=2640) Adjuvant chemotherapy (n=684) Characteristic
Adjusted for
propensity scores
Not adjusted for
propensity scores
0.96 0.02 73.4 (5.1) 71.5 (4.3) Mean (SD) age (years)
0.99 0.89 1181 (45) 304 (44) Women
Race or ethnicity:
0.98 0.04 2323 (88) 609 (89) White
129 (5) 44 (6) African-American
35 (1) —* Hispanic
152 (6) — Other
0.98 0.001 1615 (61) 465 (68) Married
Median income in area of residence:
0.98 0.21 617 (23) 137 (20) Lowest fourth
681 (26) 177 (26) Second fourth
639 (24) 167 (25) Third fourth
696 (27) 201 (29) Highest fourth
Comorbidity score†:
0.99 0.05 1065 (40) 313 (46) 0-1
898 (34) 222 (32) >1-1.5
266 (10) 56 (8) >1.5-2.5
411 (16) 93 (14) >2.5
0.96 0.04 91 (13) 437 (17) Home services
Histology:
0.98 0.005 1251 (47) 374 (55) Adenocarcinoma
163 (6) 39 (6) Bronchioloalveolar cell carcinoma
956 (36) 209 (31) Squamous cell carcinoma
172 (7) 32 (4) Large cell carcinoma
98 (4) 30 (4) Other
Tumour location:
0.95 0.40 1483 (56) 378 (55) Upper lobe
105 (4) 27 (4) Middle lobe
913 (35) 231 (34) Lower lobe
139 (5) 48 (7) Other
Cancer stage:
0.98 <0.001 362 (14) 80 (12) IIA
1024 (39) 216 (32) IIB
1254 (48) 388 (56) IIIA
Type of surgery:
0.99 0.06 2256 (85) 604 (88) Lobectomy
384 (15) 80 (12) Pneumonectomy
Postoperative radiation:
—‡ <0.001 1172 (44) 417 (61) Yes
1468 (56) 267 (39) No
*Exact numbers not reported to maintain patient confidentiality.
†Deyo adaptation of Charlson comorbidity index.
21-23
‡Radiation not included in propensity score model as it is not a pre-treatment characteristic.
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RESEARCHTable 2| Comparison of survival in patients treated with and without adjuvant chemotherapy using propensity score analysis
Hazard ratio (95% CI)
Model Adjusted for radiation therapy Not adjusted for radiation therapy
Primary analysis
Entire cohort:
0.77 (0.69 to 0.85) 0.80 (0.72 to 0.89) Adjusting for propensity scores
0.77 (0.69 to 0.85) 0.81 (0.73 to 0.89) Stratified by propensity score fifths
0.74 (0.66 to 0.82) 0.78 (0.70 to 0.87) Matched analysis
Secondary analyses
Patients treated with radiation:
— 0.77 (0.68 to 0.88) Adjusting for propensity scores
— 0.77 (0.68 to 0.88) Stratified by propensity score fifths
— 0.75 (0.66 to 0.86) Matched analysis
Patients not treated with radiation:
— 0.77 (0.64 to 0.91) Adjusting for propensity scores
— 0.76 (0.64 to 0.91) Stratified by propensity score fifths
— 0.74 (0.62 to 0.89) Matched analysis
Stage II disease:
0.67 (0.57 to 0.79) 0.71 (0.60 to 0.83) Adjusting for propensity scores
0.66 (0.56 to 0.78) 0.70 (0.60 to 0.83) Stratified by propensity score fifths
0.67 (0.56 to 0.78) 0.70 (0.60 to 0.83) Matched analysis
Stage IIIA disease:
0.85 (0.74 to 0.98) 0.88 (0.77 to 1.00) Adjusting for propensity scores
0.86 (0.75 to 0.98) 0.89 (0.78 to 1.02) Stratified by propensity score fifths
0.83 (0.72 to 0.95) 0.86 (0.75 to 0.98) Matched analysis
Age <70 years:
0.72 (0.60 to 0.86) 0.74 (0.62 to 0.88) Adjusting for propensity scores
0.73 (0.61 to 0.87) 0.75 (0.63 to 0.90) Stratified by propensity score fifths
0.72 (0.61 to 0.86) 0.76 (0.63 to 0.90) Matched analysis
Age 70-79 years:
0.78 (0.68 to 0.89) 0.82 (0.71 to 0.94) Adjusting for propensity scores
0.78 (0.69 to 0.90) 0.83 (0.73 to 0.96) Stratified by propensity score fifths
0.77 (0.67 to 0.89) 0.82 (0.71 to 0.93) Matched analysis
Age ≥80 years:
1.24 (0.80 to 1.99) 1.33 (0.86 to 2.06) Adjusting for propensity scores
1.22 (0.78 to 1.90) 1.32 (0.84 to 2.05) Stratified by propensity score fifths
1.29 (0.80 to 2.08) 1.46 (0.91 to 2.34) Matched analysis
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RESEARCHTable 3| Sensitivity analysis of potential effect of poor functional status on effectiveness of adjuvant chemotherapy
Hazard ratio for chemotherapy adjusted for functional status (95%
CI)
Hazard ratio for poor functional
status†
Poor functional status (%)*
Chemotherapy No chemotherapy
0.84 (0.76 to 0.93) 1.5 5 15
0.88 (0.79 to 0.98) 1.5 5 25
0.85 (0.76 to 0.94) 1.5 7.5 20
0.87 (0.78 to 0.97) 1.5 7.5 25
0.84 (0.75 to 0.93) 1.5 15 25
0.85 (0.77 to 0.95) 1.5 25 40
0.86 (0.77 to 0.95) 1.75 5 15
0.87 (0.78 to 0.97) 1.75 7.5 20
0.90 (0.81 to 1.00) 1.75 7.5 25
0.85 (0.76 to 0.95) 1.75 15 25
0.88 (0.79 to 0.97) 1.75 25 40
0.87 (0.79 to 0.97) 2.0 5 15
0.89 (0.80 to 0.99) 2.0 7.5 20
0.93 (0.84 to 1.03) 2.0 7.5 25
0.87 (0.78 to 0.97) 2.0 15 25
0.90 (0.81 to 0.99) 2.0 25 40
*Functional status according to Eastern Co-operative Oncology Group functional status >2.
†Compared with good functional status.
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RESEARCHTable 4| Admissions to hospital for chemotherapy related serious adverse events among study participants
Odds ratio (95% CI) adjusted for
propensity scores Odds ratio (95% CI)
No (%) of patients admitted with adverse event
Adverse events No adjuvant chemotherapy Adjuvant chemotherapy
2.0 (1.3 to 3.1) 1.8 (1.2 to 2.7) 79 (3.0) 36 (5.3) Infection
17.1 (7.6 to 38.1) 15.6 (7.1 to 34.1) ≤11 (<1)* >30 (>4.4) Neutropenia
1.6 (0.4 to 5.7) 1.7 (0.5 to 5.6) ≤11 (<1)* ≤11 (≤1.6) Fever
1.9 (1.3 to 2.8) 1.8 (1.3 to 2.7) 97 (3.6) 46 (6.7) Dehydration
2.6 (1.2 to 5.3) 2.9 (1.5 to 5.8) 20 (0.8) 15 (2.1) Nausea or emesis
3.6 (2.5 to 5.2) 3.1 (2.2 to 4.4) 78 (3.0) 59 (8.6) Anaemia
8.3 (1.7 to 40.4) 5.1 (1.1 to 23.1) ≤11 (<1)* ≤11 (≤1.6) Thrombocytopenia
0.7 (0.2 to 2.4) 0.6 (0.2 to 2.1) 19 (0.6) ≤11 (≤1.6) Renal dysfunction
79.7 (9.9 to 635.9) 47.1 (6.1 to 363.1) ≤11 (<1)* ≥11 (≥1.7)
Unspecified adverse events of
systemic therapy
*Exact numbers not reported to maintain patient confidentiality.
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